Showing 1,521 - 1,540 results of 109,547 for search '(( a point decrease ) OR ( 5 ((((nn decrease) OR (a decrease))) OR (we decrease)) ))', query time: 1.60s Refine Results
  1. 1521

    Strains used in this study. by Xin Zhou (54275)

    Published 2024
    “…Here, we found that the ergosterol biosynthesis gene <i>ERG251</i> is a hotspot for point mutations during adaptation to antifungal drug stress within two distinct genetic backgrounds of <i>Candida albicans</i>. …”
  2. 1522

    Primers used in this study. by Xin Zhou (54275)

    Published 2024
    “…Here, we found that the ergosterol biosynthesis gene <i>ERG251</i> is a hotspot for point mutations during adaptation to antifungal drug stress within two distinct genetic backgrounds of <i>Candida albicans</i>. …”
  3. 1523

    <i>ERG251</i> SNPs from all FLC-evolved strains. by Xin Zhou (54275)

    Published 2024
    “…Here, we found that the ergosterol biosynthesis gene <i>ERG251</i> is a hotspot for point mutations during adaptation to antifungal drug stress within two distinct genetic backgrounds of <i>Candida albicans</i>. …”
  4. 1524
  5. 1525
  6. 1526
  7. 1527
  8. 1528
  9. 1529
  10. 1530
  11. 1531

    Data extraction grid. by Heloisa Ricci Conesa (18291210)

    Published 2024
    “…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”
  12. 1532

    Incidence rates of AOM cases. by Heloisa Ricci Conesa (18291210)

    Published 2024
    “…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”
  13. 1533

    Inclusion criteria. by Heloisa Ricci Conesa (18291210)

    Published 2024
    “…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”
  14. 1534

    PRISMA flow diagram for the literature search. by Heloisa Ricci Conesa (18291210)

    Published 2024
    “…No homogenous trends were identified in incidence rates across countries, or in detection of S. pneumoniae as a cause of AOM over time. There were indications of a reduction in hospitalization rates (decreases between 24.5–38.8% points, depending on country, PCV type and time since PCV introduction) and antibiotic resistance (decreases between 14–24%, depending on country), following the widespread use of PCVs over time. …”
  15. 1535
  16. 1536
  17. 1537
  18. 1538

    Heterocene Catalysts and Reaction Temperature Gradient in Dec-1-ene Oligomerization for the Production of Low Viscosity PAO Base Stocks by Ilya E. Nifant’ev (1561813)

    Published 2023
    “…A gradual decrease of the oligomerization temperature as dec-1-ene was consumed resulted in decreased dimer formation (down to 10%) and increased oligomer yields (up to 84%). …”
  19. 1539

    The effect of STOX1A on cell proliferation in the neuroblastoma cell-line SH-SY5Y. by Daan van Abel (214754)

    Published 2013
    “…<p>(A) The proliferation curve shows significantly decreased cell proliferation for STOX1A siRNA transfected SH-SY5Y cells compared to scrambled controls after 1, 2, and 3 days in culture. …”
  20. 1540

    <i>prx-5/6</i> mutations likely cause a decrease in mmBCFA degradation. by Rencheng Wang (463927)

    Published 2013
    “…<i>elo-5</i>(<i>lf</i>)<i>; Ex</i>[<i>elo-6</i>] is a transgenic strain that significantly overexpressed the <i>elo-6</i> gene and was not sufficient to suppress the L1 arrest phenotype of <i>elo-5</i>(<i>lf</i>). …”